FDA Clears Quoin's Whole-Body Study for QRX003 The FDA has approved Quoin Pharmaceuticals’ whole-body clinical trial for QRX003, targeting Netherton Syndrome. Positive trial results revealed skin healing and reduced symptoms. Financially, Quoin holds $14.1 million in cash, sufficient for operations into mid-2026, despite reporting a $9 million loss in 2024.124